Stockreport

IGC Pharma Announces Patient Enrollment at Neurostudies in Phase 2 Trial Investigating IGC-AD1

IGC Pharma, Inc.  (IGC) 
NASDAQ:AMEX Investor Relations: igcinc.us/investor-center/overview
PDF -- Advancing IGC-AD1 Toward Commercialization as a Treatment for Agitation in Alzheimer's -- POTOMAC, Md.--(BUSINESS WIRE)--IGC Pharma, Inc (NYSE American: IGC) ("IGC [Read more]